Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Tenaya Therapeutics (TNYA) delivered earnings and revenue surprises of +4.26% and -97.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?